Difference between revisions of "Profiles"
Jump to navigation
Jump to search
| (65 intermediate revisions by 3 users not shown) | |||
| Line 6: | Line 6: | ||
===[[QIBA_Profile_Stages#Stage_3:_Technically_Confirmed|Stage 3]]: Clinically Feasible (formerly Technically Confirmed) Profiles=== | ===[[QIBA_Profile_Stages#Stage_3:_Technically_Confirmed|Stage 3]]: Clinically Feasible (formerly Technically Confirmed) Profiles=== | ||
| + | *[[Media:Atherosclerosis Biomarkers Profile 2023Mar28.pdf|CT Atherosclerosis Biomarkers, Clinically Feasible Profile. March 28, 2023. doi:10.1148/QIBA/20230328]] | ||
| − | *[[Media: | + | *[[Media:QIBA CT Vol SmallLungNoduleAssessmentInCTScreening 2023.12.19.pdf|CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening, Clinically Feasible Profile. December 19, 2023. doi:10.1148/QIBA/20231219]] |
| − | *[[Media: | + | *[[Media:QIBACTVol TumorVolumeChange(2022)-20220721.pdf|CT Tumor Volume Change for Advanced Disease, Clinically Feasible Streamlined Profile including Conformance Checklists. July 21, 2022. doi:10.1148/QIBA/20220721]] |
| − | * [[Media:QIBA | + | *[[Media:QIBA DWIProfile Stage3 15Dec2022 v3.pdf| MR Diffusion-Weighted Imaging (DWI) of the Apparent Diffusion Coefficient (ADC), Clinically Feasible Profile. December 15, 2022. doi:10.1148/QIBA/20221215]] |
| − | * [[Media: | + | *[[Media:MRE-QIBAProfile-2023-11-07-CLINICALLY-FEASIBLE-maintenance.pdf|MR Elastography of the Liver, Clinically Feasible Profile: ''Maintenance draft''. November 7, 2023. doi:10.1148/QIBA/20231107]] |
| − | + | **[[Media:MRE-QIBAProfile-2022-02-14-TECHNICALLY-CONFIRMED.pdf|MR Elastography of the Liver, Clinically Feasible Profile. February 2, 2022.]] | |
| − | * [[Media:QIBA | + | *[[Media:Supplement QIBA AmyloidPET 3Jun2022 TechnicallyConfirmed.pdf|PET Amyloid, Clinically Feasible Profile. June 3, 2022. doi:10.1148/QIBA/20220603]] |
| − | |||
| − | + | *[[Media:QIBA FDG-PET Profile v114.pdf|PET/CT FDG SUV for Response to Cancer Therapy, v1.14, Clinically Feasible Profile containing updated checklist. June 15, 2023. doi:10.1148/QIBA/20230816]] | |
| + | *[[Media:QIBA FDG-PET Profile v113.pdf|PET/CT FDG SUV for Response to Cancer Therapy, v1.13, Clinically Feasible Profile. November 18, 2016.]] | ||
| + | ::*[[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.0. December, 2014.]] | ||
| − | *[[Media:QIBA | + | *[[Media:QIBA US SWS Profile 01.15.2024-clean version.pdf| US Shear Wave Speed for Liver Fibrosis, Clinically Feasible Profile. January 15, 2024. doi:10.1148/QIBA/20240115]] |
| − | :*[[Media: | + | ::*[[Media:SWS Checklists-Appendix E-12.28.2023.xlsx|Checklists - US SWS Appendix E. December 28, 2023]] |
| + | ::*[[Media:SWS Checklists-Appendix E-01.26.2023.xlsx|US SWS Checklist for Clinically Feasible Site Assessment. January 26, 2023]] | ||
| − | + | ===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles=== | |
| − | : | ||
| − | *[[Media: | + | *[[Media:QIBA CT Lung Density Profile 090420-clean.pdf| CT Lung Density 2020-09-04]] (Contains Conformance Checklists, Appendix B) 2020-10-23 |
| + | ::*[[Media:QIBA CT Lung Density Protocols-Appendix E.xlsx|Protocols - Appendix E:CT Lung Density 2019-06-26]] | ||
| − | *[[Media: | + | *[[Media:DCE-MRI Quantification Profile v1.0.pdf| MR DCE Quantification (V.1) 2012-08-08]] |
| − | *[[Media:QIBA DSC-MRI Stage2-Consensus Profile.pdf| MR Dynamic Contrast Susceptibility | + | *[[Media:QIBA DSC-MRI Stage2-Consensus Profile.pdf| MR Dynamic Contrast Susceptibility 2020-10-22]] |
| − | *[[Media:QIBA Profile MSK-Cartilage-Stage2 Profile.pdf| MR MSK | + | *[[Media:QIBA Profile MSK-Cartilage-Stage2 Profile.pdf| MR MSK Cartilage for Joint Disease 2021-09-25]] |
| − | *[[Media:001.QIBA SPECT Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf| SPECT Ioflupane for Neurodegenerative Disease | + | *[[Media:001.QIBA SPECT Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf| SPECT Ioflupane for Neurodegenerative Disease 2017-06-26]] |
| − | *[[Media:002.QIBA SPECT Ioflupane Profile v2.0.2019 10 15.pdf| SPECT Ioflupane for Neurodegenerative Disease | + | *[[Media:002.QIBA SPECT Ioflupane Profile v2.0.2019 10 15.pdf| SPECT Ioflupane for Neurodegenerative Disease 2019-10-15]] |
| − | :*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx| | + | ::*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklists - SPECT Ioflupane]] |
*[[Media:QIBA SPECT 99mTC Profile 10.21.19.pdf|SPECT-CT: Estimating the Concentration of 99mTc Based Imaging Biomarkers in Large and Small Volumes of Interest Profile 2019-10-21]] | *[[Media:QIBA SPECT 99mTC Profile 10.21.19.pdf|SPECT-CT: Estimating the Concentration of 99mTc Based Imaging Biomarkers in Large and Small Volumes of Interest Profile 2019-10-21]] | ||
| − | *[[Media:QIBA US | + | *[[Media:QIBA US VBF Profile 01.05.2024-Consensus.pdf| US Volume Blood Flow Profile, Consensus version 2024-01-05]] |
| − | |||
| − | + | *[[Media:QIBA PDFF Profile Stage2 FINAL.pdf|MRI-Based Proton Density Fat Fraction (PDFF) of the Liver 2023-12-04]] | |
| − | + | *[[Media:QIBA DCE-Profile - v2.0 - Consensus Document.pdf|MR DCE-MRI Quantification (DCEMRI-Q) (V.2) 2023-12-06]] | |
| − | *[[Media:QIBA | + | ===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles=== |
| + | *[[Media:QIBA fMRI Profile 1 PC-rev1.pdf|fMRI for Sensorimotor Mapping 2017-06-19]] (comments '''closed''' on December 31, 2017) | ||
| − | |||
| − | + | '''[[Comment Resolutions]]''' <font color="black">are posted for '''Past Public Comments''' and '''Past Technical Confirmations'''. | |
| + | '''Tools to aid Biomarker Committees in collating these comments:''' | ||
| + | * {Public Comment Resolution} - '''Editor''' collates all comments into a '''resolution spreadsheet''' (see '''[https://docs.google.com/spreadsheets/d/1o3_ssHHIABGKNesUJ_-jL5RYqSx9Eq4o6C2dlIsHQo4/edit?usp=sharing Google Sheet template)]''' | ||
| + | * {Site responses for Stage 3} - '''Field Test Leader''' collates all Feedback comments into a '''[https://docs.google.com/spreadsheets/d/1JW-_iJ7vTJvCf1-y4wsxZ_coO8Po2zWqMNDNrBVyUXM/edit?usp=sharing Feedback Resolution spreadsheet]''' | ||
| + | ''' | ||
| − | |||
| + | '''[[Media:QIBA Profiles and Clinical Applications-v01Nov2023-2.xlsx|QIBA Profiles and Clinical Applications]]''' | ||
| + | |||
====Format for Citing Profiles==== | ====Format for Citing Profiles==== | ||
Cite QIBA Profile documents as: | Cite QIBA Profile documents as: | ||
| − | :''Specific QIBA Biomarker Committee. Specific Profile Title'', Quantitative Imaging Biomarkers Alliance. '' | + | :''Specific QIBA Biomarker Committee. Specific Profile Title'', Quantitative Imaging Biomarkers Alliance. ''Profile Stage''. ''Date''. Available from: ''URL'' |
Example: | Example: | ||
| Line 75: | Line 82: | ||
| − | ==== See Also==== | + | ====See Also==== |
*[[How to use QIBA Profiles]] | *[[How to use QIBA Profiles]] | ||
*[[Committees|Biomarker Committee]] pages may also have links to DRAFT Profile documents for the next Stage. | *[[Committees|Biomarker Committee]] pages may also have links to DRAFT Profile documents for the next Stage. | ||
Latest revision as of 19:24, 18 April 2024
Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.
Profiles may be of use at any Stage.
Stage 3: Clinically Feasible (formerly Technically Confirmed) Profiles
- PET/CT FDG SUV for Response to Cancer Therapy, v1.14, Clinically Feasible Profile containing updated checklist. June 15, 2023. doi:10.1148/QIBA/20230816
- PET/CT FDG SUV for Response to Cancer Therapy, v1.13, Clinically Feasible Profile. November 18, 2016.
Stage 2: Consensus Profiles
- CT Lung Density 2020-09-04 (Contains Conformance Checklists, Appendix B) 2020-10-23
Stage 1: Public Comment Profiles
- fMRI for Sensorimotor Mapping 2017-06-19 (comments closed on December 31, 2017)
Comment Resolutions are posted for Past Public Comments and Past Technical Confirmations.
Tools to aid Biomarker Committees in collating these comments:
- {Public Comment Resolution} - Editor collates all comments into a resolution spreadsheet (see Google Sheet template)
- {Site responses for Stage 3} - Field Test Leader collates all Feedback comments into a Feedback Resolution spreadsheet
QIBA Profiles and Clinical Applications
Format for Citing Profiles
Cite QIBA Profile documents as:
- Specific QIBA Biomarker Committee. Specific Profile Title, Quantitative Imaging Biomarkers Alliance. Profile Stage. Date. Available from: URL
Example:
- QIBA MR Biomarker Committee. MR Elastography of the Liver, Quantitative Imaging Biomarkers Alliance. Profile Stage: Consensus. June 6, 2019. Available from: http://qibawiki.rsna.org/index.php/Profiles
Statements of Endorsement
See Also
- How to use QIBA Profiles
- Biomarker Committee pages may also have links to DRAFT Profile documents for the next Stage.
- Profile Conformance describes how sites and products claim conformance to a Profile.
- QIBA Profile Template shows the structure, rationale and content of a Profile (show "All Markup" to see guidance in the Word comments)